Attovia Therapeutics, Inc.
ATTO · Price history
Price at last available close
$15.00
−$2.65 (-15.01%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Attovia Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
How they make money
Attovia Therapeutics is a clinical-stage biopharmaceutical company that generates no commercial revenue. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its proprietary ATTOBODY biologics platform for immune-mediated diseases.
Products & services
The company is developing a pipeline of biotherapeutics including ATTO-1310 (anti-IL-31 for chronic pruritic diseases), ATTO-2306 (bispecific targeting IL-31 and IL-13), and ATTO-1091 (trispecific targeting TL1A, IL-23p19, and integrin a4b7).
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the production of its clinical-stage product candidates.Source
Strengths
- Proprietary ATTOBODY biologics platformSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
28
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
45
Weak
Financial Strength
22
Business Quality / Moat
100
Management
40
Growth Quality
9
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
44
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
54/100
Building Historical Record
Model Score 54/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Insider activity signal is favorable
- •M&A headline · Aug 17, 2026
- •Valuation is a weaker part of the current profile
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for ATTO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving ATTO's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can ATTO fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ATTO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ATTO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ATTO's current valuation?
Essential Investment Snapshot
Wall Street Score
28
Opportunity Score
44
Market Cap
$684.8M
P/E Ratio
-7.6
EPS
$-1.89
52-Week High
$28.00
52-Week Low
$12.94
Analyst Target
$45.00
Shares Outstanding
43.0M
Total Revenue
$450K
Total Debt
$4.3M
Dividend
No current dividend
Liquidation Value / Share
$2.62
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ATTO
Detected from reported data — verify before acting.M&A headline · Aug 17, 2026
Attovia Therapeutics (NASDAQ:ATTO) Director Acquires $1,785,000.00 in Stock — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Defense WorldCommunity Sentiment
0 active · 0 total callsNo personal call yet on ATTO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary ATTOBODY biologics platform.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Clinical development and regulatory approval risks.
- −Dependence on additional capital to fund operations.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
29
Oct 1, 2026
Change
-1.1
points
Current Score
28
Oct 23, 2026
Category Changes
ATTO decreased 1.1 points because some fundamentals weakened.
Projected Score
Projected Score
33
Projected Change
+4.5 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.5 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$15.00
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | $450K | $1.4M | $0.00 |
| Cost of Revenue | $631K | $804K | $313K |
| Gross Profit | -$181K | $546K | -$313K |
| Research & Development | $61.1M | $54.2M | $33.9M |
| SG&A Expenses | $13.2M | $13.6M | $7.4M |
| Operating Expenses | $74.3M | $67.7M | $41.2M |
| EBITDA | -$73.6M | -$66.4M | -$41.2M |
| Operating Income | -$74.5M | -$67.2M | -$41.6M |
| Interest Expense | $0.00 | $0.00 | $0.00 |
| Income Before Tax | -$68.9M | -$60.6M | -$39.8M |
| Income Tax Expense | $0.00 | $0.00 | $0.00 |
| Net Income | -$68.9M | -$60.6M | -$39.8M |
| Basic EPS | $-1.89 | $-1.42 | $-1.05 |
| Basic Shares | 45.65M | 43.03M | 43.03M |
| Diluted Shares | 45.65M | 43.03M | 43.03M |
Earnings Summary
Revenue
$450000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.45
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
No material change
Cash Change
No material change
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Potential Score Impact
Pressure indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 19.6%. Cash was essentially unchanged. Total debt was essentially unchanged.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Attovia Therapeutics to Participate in Upcoming Investor Conferences
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Rumor Mill · ATTO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial